Clinical Validation of the sFlt-1:PlGF Ratio as a Biomarker for Preeclampsia Diagnosis in a High-Risk Obstetrics Unit
The Journal of Applied Laboratory Medicine · 04.05.2023 · 8 (3) · 457-468
DOI: 10.1093/jalm/jfad003 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Applied Laboratory Medicine, online erschienen am 03.03.2023. Verfasst von Jessica J Miller und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Hypertension, Pre-Eclampsia. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Background
Preeclampsia is a multisystem disorder defined by new onset of hypertension with proteinuria after 20 weeks gestation. In part due to dysregulation of pro-angiogenic factors (e.g., placental growth factor [PlGF]) and anti-angiogenic factors (e.g., soluble fms-like tyrosine kinase 1 [sFlt-1]), preeclampsia results in decreased placental perfusion. An increased sFlt-1:PlGF ratio is associated with increased risk of preeclampsia. In this study, we evaluated sFlt-1:PlGF cutoffs and evaluated the clinical performance of sFlt-1:PlGF for predicting preeclampsia. Methods sFlt-1:PlGF results from 130 pregnant females with clinical suspicion of preeclampsia were used to evaluate the diagnostic accuracy of different sFlt-1:PlGF cutoffs and to compare the clinical performance of sFlt-1:PlGF to traditional preeclampsia markers (proteinuria and hypertension). Serum sFlt-1 and PlGF were measured using Elecsys immunoassays (Roche Diagnostics) and preeclampsia diagnosis was verified by expert chart review.
Results
A sFlt-1:PlGF cutoff of >38 yielded the greatest diagnostic accuracy of 90.8% (95% CI, 85.8%–95.7%). Using a cutoff of >38, sFlt-1:PlGF exhibited a greater diagnostic accuracy than traditionally used parameters such as new or worsening proteinuria or hypertension (71.9% and 68.6%, respectively). sFlt-1:PlGF >38 exhibited a negative predictive value (NPV) of 96.4% for rule-out of preeclampsia within 7 days, and a positive predictive value (PPV) of 84.8% for predicting preeclampsia within 28 days.
Conclusions
Our study shows the superior clinical performance of sFlt-1:PlGF over hypertension and proteinuria alone to predict preeclampsia at a high-risk obstetrical unit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
- DynaLIFE Medical Labs, Edmonton, AB, Canada.
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.
- Department of Obstetrics and Gynaecology, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, ON, Canada.
- Department of Medicine, Sunnybrook Health Sciences Centre and University of Toronto, Glomerulonephritis and Specialty Clinics, Ontario Renal Network, Toronto, ON, Canada.
- Precision Medicine and Therapeutics Program-Laboratory Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
ORCID-Profile: Paul M Yip, Lei Fu
Zitieren
APA
Miller, J. J., Higgins, V., Melamed, N., Hladunewich, M., Ma, L., Yip, P. M., & Fu, L. (2023). Clinical Validation of the sFlt-1:PlGF Ratio as a Biomarker for Preeclampsia Diagnosis in a High-Risk Obstetrics Unit. The Journal of Applied Laboratory Medicine, 8(3), 457-468. https://doi.org/10.1093/jalm/jfad003
Vancouver
Miller JJ, Higgins V, Melamed N, Hladunewich M, Ma L, Yip PM, et al. Clinical Validation of the sFlt-1:PlGF Ratio as a Biomarker for Preeclampsia Diagnosis in a High-Risk Obstetrics Unit. The Journal of Applied Laboratory Medicine. 2023;8(3):457-468. doi:10.1093/jalm/jfad003
BibTeX
@article{Miller2023,
author = {Miller, Jessica J and Higgins, Victoria and Melamed, Nir and Hladunewich, Michelle and Ma, Liyan and Yip, Paul M and Fu, Lei},
title = {Clinical Validation of the sFlt-1:PlGF Ratio as a Biomarker for Preeclampsia Diagnosis in a High-Risk Obstetrics Unit},
journal = {The Journal of Applied Laboratory Medicine},
year = {2023},
volume = {8},
number = {3},
pages = {457--468},
doi = {10.1093/jalm/jfad003}
}
EUVIMED